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Summary Recently, we reported the anti-angiogenic action along with anti-tumour activity of TNP-470
(AGM-1470). In this study, the effect of TNP-470 on the growth of human umbilical vein endothelial (HUVE)
cells was examined. TNP-470 inhibited the growth of HUVE cells in a biphasic manner. The inhibition was
cytostatic in the first phase (complete inhibition at 300 pgml' to 3 fig ml-' with an IC50 of 15 pgml-') and
cytotoxic in the second phase ( > 30 ,ug ml-'). The cytostatic inhibition of HUVE cell growth by TNP-470 was
durable after washing out TNP-470 in culture. Incorporation of thymidine but not uridine and leucine by
HUVE cells was inhibited in the first phase, while that of all three compounds was inhibited in the second
phase. Human and rat endothelial cells among various types of cells were the most sensitive to the cytostatic
inhibition, while differences in the cytotoxic inhibition were minimal. These results suggest that TNP-470
exerts its specific anti-angiogenic action by inhibiting cytostatically growth of endothelial cells in a relatively
specific manner.
Angiogenesis, the formation of new blood vessels, partici-
pates in many pathological states such as diabetic retino-
pathy, arthritis, inflammation and solid tumour (Folkman,
1985, 1990). In particular, it is thought that angiogenesis is
critical for the development and growth of solid tumour.
Recent study shows that there is a highly significant associa-
tion of microvessel density with overall survival and relapse-
free survival in patients with breast tumour (Weidner et al.,
1992). Therefore, intensive efforts in many laboratories have
been focused on finding potent anti-angiogenic agents with
anti-tumour activity and on developing anti-tumour agents
with a novel mechanism of action: to shut off delivery of
nutrients, oxygen and growth factors. Some angiogenesis
inhibitors including agents with anti-tumour activity have
been reported (Bicknell & Harris, 1991; Klagsbrun &
D'Amore, 1991). However, no satisfactory agents for clinical
use have yet been reported (Maione & Sharpe, 1990).
Recently, we reported the anti-angiogenic action of fuma-
gillin, a natural product of Aspergillus fumigatus, and its
potent analogue TNP-470, which also inhibited tumour
growth in vivo (Ingber et al., 1990; Kusaka et al., 1991).
TNP-470 was demonstrated to selectively inhibit the capil-
lary-like tube formation of endothelial cells with a minimal
effect on non-endothelial cell growth at 1-1,000 ng ml'
(Kusaka et al., 1991). In this study, the inhibitory action of
TNP-470 on endothelial cell growth was examined to clarify
the mechanism of its anti-angiogenic and anti-tumour
actions.
Materials and methods
Reagents
Basic fibroblast growth factor (bFGF) from bovine brain
was purchased from R&D Systems (Minneapolis, USA).
[6-3H]thymidine (185 GBq mmol-'), [5-3H]uridine (999 GBq
mmolh') and L-[4,5-3H]leucine (5.18 TBq mmol-1) were
obtained from Amersham Japan (Tokyo, Japan). RNAse A
and propidium idodide were purchased from Sigma (St
Louis, MO, USA).
Cells and culture
Human umbilical vein endothelial (HUVE) cells and endo-
thelial cell growth medium (E-GM) were purchased from
Kurabo (Osaka, Japan). Human embryonic lung fibroblast
(HEL) cells, human squamous cell carcinoma (HSC-1) cells
and D14 mouse angiosarcoma cells were kindly provided by
Dr Yamane of Tohoku University, Dr Kuroki of Tokyo
University and Dr Kikuchi of Sapporo Medical College
respectively. HL-60 human leukaemia cells, Walker 256 rat
carcinoma cells and Chinese hamster ovary (CHO) cells were
purchased from Dainippon Pharmaceuticals (Osaka, Japan).
The original cells were derived from the American Type
Culture Collection. Rat endothelial cells from adipose tissue,
rat smooth muscle cells from the aorta and M5076 mouse
reticulum cell sarcoma were kindly provided by Drs Saijo,
Ikeda and Ootsu in our laboratories respectively. Minimum
essential medium (MEM), Dulbecco's modified MEM
(DMEM), Ham's F12, RPMI-1640, leucine-free RPMI-1640
and Ca2+, Mg2'-free phosphate-buffered saline (PBS(-))
were obtained from Flow Laboratories (Irvine, UK). GIT
medium was purchased from Wako Pure Chemicals (Osaka,
Japan). Fetal bovine serum (FBS) and horse serum were
purchased from Whittaker-Rioproducts (Walkersville, USA).
Growth inhibition assay ofvarious types ofcells
All cells were maintained in 100 mm cell cuture dishes. For
the cell growth inhibition assay, cells were trypsinised and
plated in 24-well cell culture plates and cultured in a humidi-
fied atmosphere of 95% air and 5% carbon dioxide at 37°C.
The plate for HUVE cells was precoated with gelatin. HUVE
cells (5 x 103 cells) were cultured in E-GM supplemented
with 2 ng ml' bFGF; rat endothelial cells (2 x 103 cells)
were cultured in a mixture of E-GM and DMEM supple-
mented with 10% FBS (1:1); rat smooth muscle cells (7 x 103
cells) and HEL cells (4 x 103 cells) were cultured in MEM
supplemented with 10% FBS; HSC-1 cells (1 x 104 cells) were
cultured in GIT medium; HL-60 cells (5 x 103 cells) were
cultured in RPMI-1640 supplemented with 10% FBS; CHO
cells (5 x 103 cells) were cultured in Ham's F12 supplemented
with 10% FBS; D14 cells (1 x 103 cells) and Walker 256 cells
(4 x 103 cells) were cultured in DMEM supplemented with
10% FBS; M5076 cells (5 x 103 cells) were cultured in
DMEM supplemented with 10% horse serum. After the cells
adhered to the plate, TNP-470 dissolved in dimethylsulphox-
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ide (a final concentration of 0.1%) was added to the cultures.
Four or 5 days later, cells were trypsinised and counted in a
Coulter Counter ZM (Coulter Electronics, Hialeah, FL,
USA). In some experiments, the MTT method was used to
determine cell numbers (Mosman, 1983). HUVE cells were
plated into 96-well cell culture plates. At the end of culture,
10t l of 1Omgml-' MTT solution was added to the culture.
After the additional 4 h incubation, 1001l of 10% sodium
dodecyl sulphate (SDS) solution was added to the culture.
The absorbance at 495 nm was determined using Multiskan
MCC (Flow Laboratory).
Determination ofDNA, RNA andprotein syntheses in HUVE
cells
HUVE cells (2 x 103 cells) were plated into 96-well Corning
cell culture plates precoated with gelatin, and TNP-470 was
added to the cultures the next day. Before 4 h from the
indicated time, [6-3H]thymidine (74 kBq per well), [5-3H]-
uridine (37 kBq per well) or L-[4,5-3H]leucine (74 kBq per
well) was added to the wells. In the case of leucine, the
medium was replaced with a leucine-poor medium (E-GM-
leucine-free RPMI-1640 1:9) containing TNP-470. The plates
were incubated for an additional 4 h. Cells were washed with
PBS(-) and then trypsinised. Well contents were aspirated
onto a fibre filter, washed with distilled water and transferred
to scintillation vials using a PHD cell harvester model 290
(Cambridge Technology). The fibre filters in the vials were
dried, and a liquid scintilator was added. Radioactivity of the
fibre filter was determined.
Flow cytometric analysis
For flow cytometric anaylsis, HUVE cells (1 x 105 cells) were
plated into 100 mm cell culture dishes precoated with gelatin.
TNP-470 was added to the dishes the next day. After the
indicated time, the HUVE cells were washed with PBS(-),
trypsinised and centrifuged. The resultant cell pellets were
washed with PBS(-) and then fixed with ice-cold 70%
ethanol. The fixed HUVE cells were washed, resuspended in
PBS(-), treated with RNAse A and stained with propidium
iodide. Analysis was performed using an FACScan (Becton
Dickinson) interfaced with an HP9000 model 310 computer
(Hewlett Packard). Excitation was carried out using the
488 nm line of an air-cooled argon ion laser operating at a
continuous output of 15 mW. In order to eliminate the possi-
bility of confusing possible multiplets of GI cells with
ordinary G2 cells, CellFIT software with a doublet discrimin-
ation module was used.
Results
Biphasic inhibition ofHUVE cellgrowth by TNP-470
As shown in Figure 1, TNP-470 inhibited the growth of
HUVE cells in a biphasic manner: in the first phase, inhibi-
tion of cell growth was not associated with reduction in the
cell number below the initial plating number shown with an
arrow in Figure 1. The inhibition of HUVE cell growth by
TNP-470 in the first phase occurred in a wide range of
concentrations (complete inhibition of 0.3-3,000 ngml-'
with IC50 of 15 pg ml-') showing a plateau in the dose-
response curve. Viability of HUVE cells after incubation at
these concentrations was confirmed by the dye exclusion
method using methylene blue (data not shown). In the
second phase, growth inhibition was observed at concentra-
tions higher than 3,000 ngml-'. The inhibition in the second
phase resulted in a reduction in the cell number below the
initial plating number. The cells were stained with methylene
blue. Furthermore, HUVE cells cultured with TNP-470 at
1Ongml-' for 2 days, the concentration of the first phase,
recovered within 4 days of exchanging the medium for fresh
medium without TNP-470 (Figure 2). However, cell growth
could not recover after HUVE cells were cultured at 10 lAg
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Figure 1 Inhibition of HUVE cell growth by TNP-470. HUVE
cells were plated in 24-well plates, and TNP-470 was added to the
cultures on the next day. Five days later, the cells were trypsi-
nised and counted with a Coulter counter. The arrow indicates
initial cell number. The results are expressed as the mean and
standard deviation of four determinations. Invisible error bars
are included in the symbols. **P<0.01 as compared with the
control by using Dunnett-type test.
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Figure 2 Reversibility of the inhibition of HUVE cell growth by
TNP-470. HUVE cells were cultured for 2 days with TNP-470
(closed symbols 10 ngml-' or open symbols 10#jgml-'), washed
with fresh medium (day 3) to remove TNP-470, and the culture
was continued with (squares) or without (triangles) the inhibitor.
The cells were counted with a Coulter counter on the indicated
day. The results are expressed as the mean of duplicate deter-
minations. The difference between the mean value and the indi-
vidual value was within 15% of the mean. Control cells are
shown as open circles.
ml-', the concentration of the second phase. The results
indicate that the inhibition in the first phase is cytostatic, and
that in the second phase is cytotoxic. In other words, TNP-
470 induced cell killing at the concentration in the second
phase but not in the first phase.
Duration ofcytostatic inhibition of HUVE cell growth was
studied by changing cytostatic concentration and incubation
time. Complete inhibition of HUVE cell growth continued
for 6 days after 2 h incubation at 100 ng ml', and partial
growth inhibition was observed after 16 h incubation at
10 ng ml' (Figure 3). The cells treated with 100 ng ml'
TNP-470 regrew after longer culture (data not shown).
Selective inhibition of TNP-470 on thymidine incorporation by
HUVE cells
The effects of TNP-470 on thymidine, uridine and leucine
(marker of DNA, RNA and protein syntheses respectively)
incorporation by HUVE cells were examined to characterise
cell growth inhibition. TNP-470 suppressed [3H]thymidine
incorporation at a concentration lower than that required for
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Figure 3 Duration of endothelial cell growth inhibition by TNP-
470. HUVE cells were cultured for 2 or 16 h with TNP-470 [10
(lm) or 100 (M) ngml-h], washed and cultured without
TNP-470 until day 6. Relative cell number was determined by the
MTT method. The results are expressed as the mean and stan-
dard deviation of eight determinations. **P<0.01 as compared
with the control by using Dunnett-type test.
inhibition of either [3H]uridine or [3H]leucine incorporation
(Figure 4a). The IC50 value for this inhibition is similar to
that for inhibition of HUVE cell growth in the cytostatic
phase of inhibition. Both [3H]uridine and [3H]leucine incor-
poration were suppressed at concentrations higher than
3,000 ng ml- ', which is similar to those required for the
second-phase inhibition of HUVE cell growth. As shown in
Figure 4b, the inhibition of thymidine incorporation by
TNP-470 was not induced until after 8 h of incubation.
Longer incubation, 23 h incubation in Figure 4b, was neces-
sary for the selective inhibition.
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Flow cytometric analysis ofHUVE cellgrowth inhibition by
TNP-470
To determine if the inhibitory effects on HUVE cell growth
by TNP-470 involved an arrest of the cell growth at a
particular phase in the cell cycle, HUVE cells were cultured
with TNP-470 at 10 ng ml-' for various periods and then the
DNA content of the cells was measured by flow cytometric
analysis. The results indicated that an increased proportion
of the cells was found in the GO/GI phase and a decreased
proportion of the cells was found in G2/M and S-phases as
compared with the controls after 21 h incubation but not
after 7 h incubation (Figure 5).
Growth inhibition ofvarious types ofcells by TNP-470
TNP-470 inhibited the growth of various types of cells
besides HUVE cells (Figure 6). All types of cells exhibited
sensitivity to TNP-470 more or less with a biphasic inhibition
curve but with wide variations in extent of sensitivity. The
extent of inhibition of the first phase was variable, although
the potency of the inhibition in the second phase was similar.
Thus, different types of cells exhibited different IC50 values.
Growth of rat endothelial cells was inhibited with a similar
sensitivity to that of HUVE cells, and these endothelial cells
were the most sensitive. On the other hand, the growth
inhibition of some types of cells, especially that of tumour
cells, was very weak, indicating wide variation in sensitivity
to TNP-470 among different cell types.
Discussion
We previously reported that TNP-470 exhibited potent anti-
angiogenic activity in four different assay systems in vitro and
in vivo (Kusaka et al., 1991). In the rat thoracic vein organ
culture assay, TNP-470 selectively inhibited capillary-like
tube formation, although the mechanism of this selective
inhibition is unclear. Therefore, the effect of TNP-470 on
HUVE cell growth was examined to clarify its anti-angio-
genic activity with special reference to its endothelial cell
growth-inhibiting activity.
TNP-470 was found to inhibit the growth of HUVE cells
in a biphasic manner: the inhibition in the first phase was
reversible, indicating that this inhibition is cytostatic, and the
inhibition in the second phase was irreversible and cell
number decreased below the plated number, indicating that
this inhibition is cytotoxic. Cytostatic inhibition of TNP-470
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Figure 4 Selective inhibition of DNA synthesis by TNP-470.
HUVE cells were cultured for 18 h at varying concentrations of
TNP-470 a, or at 0.3 ng ml-' of TNP-470 for varying times b.
Then, [3H]thymidine (0), [3HJuridine (A) or [3H]leucine (0) was
added, and incubation was continued for an additional 4 h. After
incubation, HUVE cells were washed, trypsinised and transferred
onto a fibre filter. Radioactivity on the fibre filter was deter-
mined. The results are expressed as the mean and standard
deviation of four determinations. Invisible error bars are included
in the symbols. **P<0.01 as compared with the control by using
Dunnett-type test.
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Figure 5 Flow cytometric analysis of the effect of TNP-470 on
HUVE cells. HUVE cells were cultured for various periods in
lO ng ml-' TNP-470, trypsinised, fixed with 70% ethanol and
stained with propidium iodide. Analysis of DNA content was
performed with a FACScan flow cytometer.
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Figure 6 Growth inhibition on varoius types of cells by TNP-
470. Various cells were cultured with TNP-470 for 4 or 5 days.
The cells were counted with a Coulter counter. The results are
expressed as the mean of duplicate determinations. The difference
between the mean value and the individual value was within 15%
of the mean. a, HUVE cell (i), rat endothelial cell (A), human
embryonic lung fibroblast cell (0), rat smooth muscle cell (0),
mouse M5076 reticulum cell sarcoma cell (+). b, HUVE cell (0),
mouse D14 angiosarcoma cell (0), human leukaemia (HL-60)
cell (A), human squamous cell sarcoma (HSC-l) cell (El),
Chinese hamster ovary (CHO) cell (+), rat Walker 256 car-
cinoma cell (x).
on endothelial cell growth was exhibited over a wide range of
concentrations from 10 pg ml-' to 3 ,.g m1~'. This cytostatic
inhibition seems to be important for angiogenesis inhibition
by TNP-470 for the following reasons:
1. The concentration for the cytostatic inhibition rather
than the cytotoxic inhibition is similar to that for inhibi-
tion of capillary-like tube formation, which is a model of
angiogenesis in vitro (Kusaka et al., 1991).
2. Among fumagillin analogues, those having potent cyto-
static inhibitory activity against HUVE cell growth
exhibited potent anti-angiogenic activity (Marui et al.,
1992), showing a correlation between potencies of cyto-
static inhibition and anti-angiogenic action.
3. Serum concentration of TNP-470 was much lower than
that for the cytotoxic inhibition after administration of
TNP-470 to rats in a preliminary study (manuscript in
preparation). Taken together, cytostatic inhibition by
TNP-470 seems to be important for its anti-angiogenic
and anti-tumour activities.
Cytostatic inhibition of endothelial cell growth by TNP-
470 continued for several days even after TNP-470 was
removed from the culture medium. The sustained inhibition
explains why TNP-470 is effective against tumour growth and
metastasis not only upon daily administration but also upon
intermittent administration in vivo. In fact, TNP-470 was
effective even when administered once a week (unpublished
data).
Angiogenesis inhibitors have been reported (Bicknell &
Harris, 1991; Klagsbrun & D'Amore, 1991). Some of them
have inhibitory activity on endothelial-cell growth. However,
low molecular weight inhibitors of angiogenesis with cyto-
static inhibitory activity of endothelial cell growth are scarce.
Furthermore, the cytostatic inhibition by TNP-470 is durable
after washing out TNP-470 in culture. These characteristics
of TNP-470 are beneficial to clinical use. The endothelial cell
growth inhibition of the cytostatic type by TNP-470 may be
useful because of its lack oftoxicity in the treatment of other
angiogenic diseases such as arthritis (Peacock et al., 1992).
To characterise the inhibition ofendothelial cell growth by
TNP-470, biosynthesis of macromolecules (DNA, RNA and
protein) in the cells was examined. It was found that TNP-
470 selectively suppressed DNA synthesis over a wide range
of concentrations. Concentrations for the DNA-specific inhi-
bition were similar to those for the cytostatic inhibition of
endothelial cell growth. On the other hand, all of DNA,
RNA and protein syntheses of HUVE cells were inhibited at
the cytotoxic concentration. The results of flow cytometric
analysis confirmed the inhibitory action on DNA synthesis
by TNP-470. TNP-470 caused an increased proportion of
cells in GO/G1 phases and a decreased proportion in the
G2/M and S-phases after more than 21 h of incubation.
Selective inhibition of DNA synthesis by TNP-470 may be a
result of arrest in the GO/GI phases and related to the
cytostatic inhibition and the low toxicity of this compound.
The mechanism of cell growth inhibition associated with
selective suppression of DNA synthesis is not yet clear. TNP-
470 arrested HUVE cells in the GO/GI phases and suppressed
DNA synthesis after a lag time of 8 h. Therefore, TNP-470
may function by a mechanism mediated by protein synthesis
or protein depletion. In a preliminary experiment, cyclohex-
imide could not rescue growth inhibition by TNP-470, indi-
cating that new protein synthesis is unlikely to be involved in
the mechanism of action of TNP-470. The ICs for cytostatic
growth inhibition is 15 pgml-l (37 pM). This low value sug-
gests that TNP-470 may interact in a high-affinity manner
with specific molecule(s) that inhibit DNA synthesis either
directly or indirectly. Various types of cells showed different
sensitivities to TNP-470. Generally, the cell needs growth
factor(s) to grow and has signal pathway(s) via receptor(s) on
the cell surface for each growth factor(s). So, this different
sensitivity may indicate that TNP-470 can discriminate
between some unknown responsive sites in growth signal
pathways, and the sensitivity or number of the responsive
sites may vary depending on the cell type. Furthermore, the
relatively low sensitivity of tumour cells to TNP-470 may
indicate that the product(s) of proto-oncogene(s) or those of
tumour-suppressor gene(s) are involved in the action ofTNP-
470.
In conclusion, the angiogenesis inhibitor TNP-470 inhibit-
ed endothelial cell growth in a biphasic manner. The cyto-
static inhibition is accompanied by selective suppression of
DNA synthesis. Endothelial cells were the most sensitive to
TNP-470. The potent cytostatic inhibition with relative cell
specificity on endothelial cell growth by TNP-470 may be
related to its anti-angiogenic and anti-tumour activities with
relatively few side-effects.
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